当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Characteristics of the inhibition of human promyelocytic leukaemia HL60 cell growth by S-D-lactoylglutathione in vitro.

Characteristics of the inhibition of human promyelocytic leukaemia HL60 cell growth by S-D-lactoylglutathione in vitro.

Abstract：

:The mechanism of the inhibition of proliferation of human leukaemia 60 (HL60) cells by S-D-lactoylglutathione in vitro was investigated. The median inhibitory concentration IC50 value was 66 microM (95% C.I. 50-87 microM; n = 18). The inhibition of leukaemia cell growth required exposure of HL60 cells to S-D-lactoylglutathione (and metabolites) for 12 h, with maximum growth inhibition achieved after 24 h. Removal and replacement of culture medium within the initial 12 h of culture prevented inhibition of growth and toxicity. S-D-lactoylglutathione was consumed within the initial 3 h of culture. Pretreatment of culture medium containing 10% foetal calf serum for 3 h produced no subsequent inhibition of HL60 cell growth. Incubation of HL60 cells in culture medium with low serum content (5% v/v) produced a decreased rate of cell proliferation and a decreased response to S-D-lactoylglutathione. S-D-lactoylglutathione inhibited uptake of 3H-thymidine into DNA in the third hour of culture where the median inhibitory concentration IC50 value was 74 microM (95% C.I. 51-102; n = 10). The mechanism of inhibition of HL60 cell growth by S-D-lactoylglutathione is unknown but may be cell cycle related, mediated by inhibition of DNA synthesis and involve an active metabolite which may be removed and/or inactivated by a change in culture medium.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Edwards L,Clelland JD,Thornalley PJ

doi

10.1016/0145-2126(93)90017-f

subject

Has Abstract

pub_date

1993-04-01 00:00:00

pages

305-10

issue

4

eissn

0145-2126

issn

1873-5835

pii

0145-2126(93)90017-F

journal_volume

17

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Effects of cytapheresis on cell cycle distribution of peripheral blood and bone marrow cells in some hematological malignancies.

    abstract：:Feulgen-DNA cytophotometry and 3H-thymidine autoradiography were used to evaluate therapeutic cytapheresis effects on cell cycle distributions of peripheral blood leukemic cells in 15 acute leukemia, 5 CML and 8 CLL patients and of bone marrow erythroblasts in 18 PV patients. Both individual cytapheresis procedures an...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90186-x

    authors： Kotelnikov VM,Kasatkina VV,Dultsina SM,Sarytcheva TG,Kalinin NN,Kovaleva LG,Poljanskaja AM,Isajev VG,Khoroshko ND,Lishmanova NG

    更新日期：1987-01-01 00:00:00

  • Enhancement of J6-1 human leukemic cell proliferation by membrane-bound M-CSF through a cell-cell contact mechanism II. Role of an M-CSF receptor-like membrane protein.

    abstract：:We have isolated an M-CSF-like membrane-associated growth factor from human leukemic J6-1 cells that can enhance the growth and colony formation of J6-1 cells in vitro. Indirect evidence suggests that this membrane-associated M-CSF-like growth factor may do so by stimulating a corresponding receptor co-expressed on th...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(97)00135-5

    authors： Wu KF,Rao Q,Zheng GG,He ZH,Ying HG,Song YH,Chen BD

    更新日期：1998-01-01 00:00:00

  • The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

    abstract：BACKGROUND:The median survival of patients with chronic myelogenous leukemia in myeloid blast crisis (MBC-CML) is poor even for patients treated with tyrosine kinase inhibitors (TKIs). DESIGN AND METHODS:We conducted a dose-escalating study of daunorubicin combined to fixed doses of IM (imatinib mesylate, 600 mg/d) an...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.leukres.2010.11.004

    authors： Deau B,Nicolini FE,Guilhot J,Huguet F,Guerci A,Legros L,Pautas C,Berthou C,Guyotat D,Cony-Makhoul P,Gardembas M,Michallet M,Hayette S,Cayuela JM,Weiss IR,Réa D,Castaigne S,Mahon FX,Guilhot F,Rousselot P

    更新日期：2011-06-01 00:00:00

  • Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.

    abstract：:Acute myeloid leukemia is an aggressive disease that arises from clonal expansion of malignant hematopoietic precursor cells of the bone marrow. Deletions on the long arm of chromosome 9 (del(9q)) are observed in 2% of acute myeloid leukemia patients. Our deletion analysis in a cohort of 31 del(9q) acute myeloid leuke...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2018.11.007

    authors： Naarmann-de Vries IS,Sackmann Y,Klein F,Ostareck-Lederer A,Ostareck DH,Jost E,Ehninger G,Brümmendorf TH,Marx G,Röllig C,Thiede C,Crysandt M

    更新日期：2019-01-01 00:00:00

  • A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis.

    abstract：:A novel Philadelphia (Ph1) chromosome positive cell line, designated KYO-1, was established from the peripheral blood of a patient with chronic myelogenous leukemia (CML) in blastic crisis. Although this line had a unique capacity to differentiate spontaneously along the erythroid and monocytoid lineages as evidenced ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(85)90314-5

    authors： Ohkubo T,Kamamoto T,Kita K,Hiraoka A,Yoshida Y,Uchino H

    更新日期：1985-01-01 00:00:00

  • 5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.

    abstract：:Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment. The AGM130 c...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.12.017

    authors： Kim WS,Lee MJ,Kim DH,Lee JE,Kim JI,Kim YC,Song MR,Park SG

    更新日期：2013-04-01 00:00:00

  • Zerumbone induces apoptosis in T-acute lymphoblastic leukemia cells.

    abstract：:Zerumbone (ZER) is a potential anticancer natural compound, isolated from Zingiber zerumbet Smith. In this investigation, the anticancer properties of ZER were evaluated on cancer cells of T-acute lymphoblastic leukemia, CEM-ss. The results showed that ZER has cytotoxic effect against CEM-ss cells with an IC(50) of 8....

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.07.025

    authors： Abdelwahab SI,Abdul AB,Mohan S,Taha MM,Syam S,Ibrahim MY,Mariod AA

    更新日期：2011-02-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract：:Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0145-2126(96)00116-6

    authors： Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期：1997-02-01 00:00:00

  • Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico.

    abstract：:This study evaluated the association of -401C/T and +452C/T polymorphisms of gamma-glutamyl hydrolase and the risk of relapse to acute lymphoblastic leukemia. Genotyping was performed in 70 children with acute lymphoblastic leukemia and 140 healthy children. An association between the -401C/T polymorphism and the risk...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.11.027

    authors： Organista-Nava J,Gómez-Gómez Y,Saavedra-Herrera MV,Rivera-Ramírez AB,Terán-Porcayo MA,Alarcón-Romero Ldel C,Illades-Aguiar B,Leyva-Vázquez MA

    更新日期：2010-06-01 00:00:00

  • Genotypic and cytogenetic study of acute myelocytic leukemia and chronic myelocytic leukemia in blast crisis: specific delta rearrangement pattern does not involve J delta gene locus.

    abstract：:We have analysed the configuration of immunoassociated genes and the karyotypes of 30 patients with acute myelocytic leukemia (AML) and 10 with chronic myelocytic leukemia in blast crisis (CML-BC). In AML, the frequencies of T-cell receptor (TcR) beta, gamma, and delta chain and immunoglobulin heavy and light chain ge...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90070-a

    authors： Akiyoshi TT,Kimura N,Uike N,Kozuru M,Tamura K,Takihara Y,Hisano S,Nishimura J,Kikuchi M

    更新日期：1991-01-01 00:00:00

  • Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.

    abstract：BACKGROUND:The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are associated with increases in janus kinase 2 (JAK2) signaling, often resulting from the JAK2 V617F mutation. LY2784544 (gandotinib) is a potent, selective, small-molecule inhibitor of JAK2 that has potential dose-dependent selectivit...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2018.06.014

    authors： Berdeja J,Palandri F,Baer MR,Quick D,Kiladjian JJ,Martinelli G,Verma A,Hamid O,Walgren R,Pitou C,Li PL,Gerds AT

    更新日期：2018-08-01 00:00:00

  • Differentiation induction in non-lymphocytic leukemia cells upon treatment with mycophenolate mofetil.

    abstract：:Inosine 5'-monophosphate (IMP) dehydrogenase catalyzes the rate-limiting reaction of guanine nucleotide biosynthesis and has been implicated in the reaction of cell growth and differentiation. We investigated the ability of mycophenolate mofetil, a prodrug of mycophenolic acid, to induce differentiation in HL-60 and U...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(00)00045-x

    authors： Inai K,Tsutani H,Yamauchi T,Fukushima T,Iwasaki H,Imamura S,Wano Y,Nemoto Y,Naiki H,Ueda T

    更新日期：2000-09-01 00:00:00

  • Deoxycytidine kinase, thymidine kinase and cytidine deaminase and the formation of Ara-CTP in leukemic cells in different phases of the cell cycle.

    abstract：:In this study we investigated the Ara-CTP-forming capacity of leukemic cells in different phases of the cell cycle. Cells from two leukemic cell lines and leukemic bone marrow cells from patients and rats (BNML model) with acute myelocytic leukemia were separated according to cell cycle phase by means of an albumin de...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(90)90164-5

    authors： Richel DJ,Colly LP,Arentsen-Honders MW,Starrenburg CW,Willemze R

    更新日期：1990-01-01 00:00:00

  • STAT6 and the regulation of CD23 expression in B-chronic lymphocytic leukemia.

    abstract：:High CD23 expression is a hallmark of B-CLL cells. It is lost during in vitro culture and can be reinduced by IL-4, albeit to a lower extent than in normal B cells. To elucidate the events controlling CD23 expression in B-CLL cells, the IL-4 mediated induction of STAT6 was investigated. Western-blot analysis demonstra...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(99)00191-5

    authors： Kneitz C,Goller M,Seggewiss R,Yaman A,Serfling E,Tony HP

    更新日期：2000-04-01 00:00:00

  • Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.

    abstract：:Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatinib and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anoma...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2005.01.009

    authors： Ali R,Ozkalemkaş F,Ozçelik T,Ozkocaman V,Ozan U,Kimya Y,Köksal N,Gülten T,Yakut T,Tunali A

    更新日期：2005-08-01 00:00:00

  • Detection of fos oncogene products by monoclonal antibody FO-120 in lymphoproliferative disorders.

    abstract：:We investigated the expression of fos oncogene proteins in lymphoproliferative disorders, using a monoclonal antibody (FO-120) that was prepared against a synthetic oligopeptide of fos protein (amino acid sequence from 127 to 152). Although peripheral blood leukocytes were rarely positive for FO-120, they were transie...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90010-6

    authors： Kanaitsuka T,Namba Y,Zu YL,Ishii K,Ashihara T,Hanaoka M,Suchi T

    更新日期：1989-01-01 00:00:00

  • Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency.

    abstract：:Mutation of the tumor suppressor PTEN results in loss of its PI3-kinase counteracting function. PI3-kinase stimulates tumor formation by PKB/Akt-mediated cell proliferation and prevention of apoptosis. PI3-kinase may also activate Rho-GTPases and their regulatory GEFs to promote invasion. Here we have analyzed the fun...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.03.034

    authors： Strumane K,Song JY,Baas I,Collard JG

    更新日期：2008-01-01 00:00:00

  • Hemopoietic features of splenectomized mice bearing IL-3 producing T cell leukemia.

    abstract：:Hemopoietic responses were studied in splenectomized mice after transplantation of the hemopoietic colony stimulating activity producing leukemia, L8313. In non-splenectomized mice, the number of peripheral leukocytes was elevated to 4 x 10(5)/mm3 after transplantation. In contrast, it was below 1.7 x 10(4)/mm3 in spl...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90159-8

    authors： Sawada H,Sugimoto K,Aramaki K,Mori KJ

    更新日期：1989-01-01 00:00:00

  • Incidence of 5' bcl-2 rearrangement in patients with B cell chronic lymphocytic leukemia from India.

    abstract：:The incidence of B cell chronic lymphocytic leukemia (B-CLL) is lower in Asian countries, including India, when compared with Western countries. The bcl-2 gene rearrangement was restricted to the 5' region and seen in only one of the 20 Indian patients analyzed. The incidence remains similar to that reported from West...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(96)00036-7

    authors： Parikh PM,Desai S,Naresh KN,Shakuntaka B,Laxminarayan K,Nair CN,Ladanyi M,Soman CS,Advani SH,Chaganti RS

    更新日期：1996-09-01 00:00:00

  • Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide.

    abstract：:We hypothesized that the lipid second messenger, ceramide, and microtubule-directed chemotherapeutic agents might engage converging pathways in inducing apoptosis. Our studies demonstrated that simultaneous treatment of Jurkat cells with paclitaxel and ceramide enhanced paclitaxel-induced cell growth inhibition. Cell ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(99)00048-x

    authors： Myrick D,Blackinton D,Klostergaard J,Kouttab N,Maizel A,Wanebo H,Mehta S

    更新日期：1999-06-01 00:00:00

  • Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.

    abstract：:Allogeneic stem cell transplantation is considered to be a curative treatment modality in patients with chronic myelogenous leukemia. However patients are at risk for relapse years after transplantation. Currently we present two patients who relapsed 16 and 24 years after allogeneic bone marrow transplantation, respec...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.03.010

    authors： Sekhri A,Liu D,Rasul M,Ahmed N,Ahmed T,Seiter K

    更新日期：2009-09-01 00:00:00

  • Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

    abstract：:Five patients from the Kyushu area in Japan with adult T-cell leukaemia (ATL) refractory to conventional chemotherapeutic agents were treated with 5 mg/m2 of the adenosine deaminase inhibitor, 2'-deoxycoformycin (DCF), intravenously (i.v.) for 3 consecutive days, followed by 5 mg/m2 i.v. weekly. Two patients showed a ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(86)90251-1

    authors： Yamaguchi K,Yul LS,Oda T,Maeda Y,Ishii M,Fujita K,Kagiyama S,Nagai K,Suzuki H,Takatsuki K

    更新日期：1986-01-01 00:00:00

  • Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML.

    abstract：:We monitored DLI treatment of 13 post-SCT relapses using quantitative competitive (QC) RT-PCR for BCR-ABL (sensitivity 10(-5)) and compared responses to DLI alone and DLI in combination with interferon-alpha (IFN). Ten relapses (one blast crisis, five cytogenetic and four molecular) were treated with DLI+IFN, three re...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(02)00280-1

    authors： Moravcová J,Nádvorníková S,Zmeková V,Michalová K,Brezinová J,Lukásová M,Vítek A,Hrabánek J,Gasová Z,Sedlácek P,Starý J

    更新日期：2003-08-01 00:00:00

  • A new method for studying cell cycle characteristics in ANLL using double-labeling with BrdU and 3HTdr.

    abstract：:Ten patients with acute nonlymphocytic leukemia (ANLL) received bromodeoxyuridine (BrdU) at 100 mg/M2 intravenously over 1 h. BrdU is incorporated into the DNA by S-phase cells and was detected by using a monoclonal anti-BrdU antibody in the bone marrow aspirate (BM) and biopsy specimens obtained at the end of the inf...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90160-3

    authors： Raza A,Maheshwari Y,Yasin Z,Mandava N,Mayers G,Preisler HD

    更新日期：1987-01-01 00:00:00

  • Use of cell surface antigen phenotype in guiding therapeutic decisions in chronic myelomonocytic leukemia.

    abstract：:The myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell diseases in which both diagnosis and prognosis are determined by cellular morphologic criteria. In some patients, prognosis is poor due to proliferation of immature cells, i.e. development of acute leukemia. An important clinical decisi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(94)90112-0

    authors： Woodlock TJ,Seshi B,Sham RL,Cyran EM,Bennett JM

    更新日期：1994-03-01 00:00:00

  • Biochemical mechanisms of deoxycoformycin toxicity in chronic leukemias.

    abstract：:The in-vitro effects of deoxycoformycin (dCF) on dATP, NAD, ATP and DNA strand breaks have been evaluated in the cells from 42 patients with various types of chronic lymphoid leukemia. These included 18 with B-cell chronic lymphoid leukemias of different types (BCL); 10 with hairy cell leukemia (HCL) and 14 with T-cel...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90140-8

    authors： Ganeshaguru K,Ho AD,Piga A,Catovsky D,Hoffbrand AV

    更新日期：1987-01-01 00:00:00

  • SOX11 as a minimal residual disease marker for Mantle cell lymphoma.

    abstract：:Recent studies have identified SOX11 as a novel diagnostic marker for mantle cell lymphoma (MCL). We quantified SOX11 by a truly mRNA specific qPCR assay in longitudinal peripheral blood samples from 20 patients and evidenced a close relationship of SOX11 expression and clinical status of the patients. In eight patien...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.04.007

    authors： Simonsen AT,Sørensen CD,Ebbesen LH,Bødker JS,Bentzen HH,Nyvold CG

    更新日期：2014-08-01 00:00:00

  • Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

    abstract：:Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs). Limited data exist on the possible effects of these drugs on subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT).The outco...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2009.04.036

    authors： Breccia M,Palandri F,Iori AP,Colaci E,Latagliata R,Castagnetti F,Torelli GF,Usai S,Valle V,Martinelli G,Rosti G,Foà R,Baccarani M,Alimena G

    更新日期：2010-02-01 00:00:00

  • Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent antileukemic activity.

    abstract：:In a previous study we reported that a new anthracycline derivative (moflomycin) exhibited a higher antileukemic activity compared to other anthracyclines, such as daunorubicin and doxorubicin. To explain the superior antileukemic effect of moflomycin and to disclose a possible structure-activity relationship, we inve...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(95)00155-7

    authors： Andrivon W,Saucier JM,Auclair C,Monneret C,Florent JC,Guillosson JJ,Nafziger J

    更新日期：1996-02-01 00:00:00

  • PDTC enables type I TRAIL signaling in type II follicular lymphoma cells.

    abstract：:Based on Bcl-X(L) overexpression studies we identified type I and type II follicular lymphoma cell lines in response to TRAIL. We demonstrate here that either amount of caspase-8 activation or Bid cleavage could not define the dependence on mitochondria. Furthermore, an inhibitor of NF-kappaB, PDTC, enabled TRAIL to a...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.09.025

    authors： Nuutinen U,Simelius N,Ropponen A,Eeva J,Mättö M,Eray M,Pellinen R,Wahlfors J,Pelkonen J

    更新日期：2009-06-01 00:00:00